(Q42725814)

5 November 2017

title

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. (English)

1 reference

5 November 2017

28

A Tefferi

1 reference

5 November 2017

A V Purandare

1

1 reference

5 November 2017

T M McDevitt

2

1 reference

5 November 2017

H Wan

3

1 reference

5 November 2017

D You

4

1 reference

5 November 2017

B Penhallow

5

1 reference

5 November 2017

X Han

6

1 reference

5 November 2017

R Vuppugalla

7

1 reference

5 November 2017

Y Zhang

8

1 reference

5 November 2017

S U Ruepp

9

1 reference

5 November 2017

G L Trainor

10

1 reference

5 November 2017

L Lombardo

11

1 reference

5 November 2017

D Pedicord

12

1 reference

5 November 2017

M M Gottardis

13

1 reference

5 November 2017

P Ross-Macdonald

14

1 reference

5 November 2017

H de Silva

15

1 reference

5 November 2017

J Hosbach

16

1 reference

5 November 2017

S L Emanuel

17

1 reference

5 November 2017

Y Blat

18

1 reference

5 November 2017

E Fitzpatrick

19

1 reference

5 November 2017

T L Taylor

20

1 reference

5 November 2017

K W McIntyre

21

1 reference

5 November 2017

E Michaud

22

1 reference

5 November 2017

C Mulligan

23

1 reference

5 November 2017

F Y Lee

24

1 reference

5 November 2017

A Woolfson

25

1 reference

5 November 2017

T L Lasho

26

1 reference

5 November 2017

A Pardanani

27

1 reference

5 November 2017

M V Lorenzi

29

1 reference

5 November 2017

publication date

21 October 2011

1 reference

5 November 2017

1 reference

5 November 2017

volume

26

1 reference

5 November 2017

issue

2

1 reference

5 November 2017

page(s)

280-288

1 reference

The JAK-STAT signaling pathway: input and output integration

5 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Canonical and non-canonical JAK-STAT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

STATs in cancer inflammation and immunity: a leading role for STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

A role for JAK2 mutations in myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Kinase drug discovery approaches in chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.292

21 January 2018

Identifiers

DOI

10.1038/LEU.2011.292

1 reference

Dimensions Publication ID

5 November 2017

1014613085

0 references

1 reference